Bristol-Myers Squibb Co vs Utilities Select Sector SPDR Fund — how do they compare? Bristol-Myers Squibb Co trades at $63.97 (market cap $129.94B), while Utilities Select Sector SPDR Fund trades at $43.81. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Utilities Select Sector SPDR Fund pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Utilities Select Sector SPDR Fund nearer its low. Which is the better fit depends on your goals.
| BMY | XLU | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | — |
52-Week High | $65.89 | $47.73 |
52-Week Low | $42.60 | $41.31 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
XLU trades at $43.74, up 1.39% with bearish technical signals from moving averages and oscillators. The ETF shows strong institutional call option activity, with 43,489 contracts traded on August 11, 2026, representing an 18% increase over typical volume. Recent news highlights XLU's positioning as an AI power demand play, with utilities gaining attention for data center electricity needs. The fund offers defensive income characteristics with dividend distributions scheduled for June 2026.
XLU faces technical headwinds but benefits from structural AI power demand growth. The ETF's defensive utility holdings provide income stability while capturing electricity infrastructure expansion. Key risks include interest rate sensitivity and regulatory changes, but institutional interest in call options suggests bullish positioning on the AI power theme.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →